Surrozen is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. Wnt signaling plays key roles in the control of development, homeostasis, and regeneration of many essential organs and tissues, and modulation of Wnt signaling has the potential for treatment of degenerative diseases and tissue injuries. Surrozen is developing tissue-specific antibodies designed to engage this existing biological repair mechanism with potential application across multiple disease areas, including inflammatory bowel disease, hepatitis, eye diseases, hearing loss, lung and airway diseases, and certain neurological disorders.
Ian Stone, Managing Director
Tel.: (619) 518-3518